$CERo CEO, Chris Ehrlich, spoke with Jed Morley of #ValiantCEO on the state of the biotechnology industry, business development, venture capital, investment banking, and SPAC experience. Read the Q&A article here: bit.ly/3MgQZUe

Check out this feature with $CERo's CEO, Chris Ehrlich, on the complexities of developing cell-based therapies with Clinical Leader. Read the full article: bit.ly/48YGCNr #LeadershipInsights #CellTherapy

In a new interview with A Further Inquiry, $CERo's CEO Chris Ehrlich discusses CER-1236, a first-in-human CER-T therapy targeting TIM-4L in relapsed/refractory #AML, and shares early Phase 1/1b insights on #CERo's phagocytic CER-T platform. Full article: bit.ly/48FwrgU

$CERo announces recent advances to the CertainT-1 #clinicaltrial that is focused on patients with #acutemyeloidleukemia (#AML). Full press release here: bit.ly/4s22sr1 #CERo #ClinicalTrials

$CERo's CEO, Chris Ehrlich, highlights how strong clinical & manufacturing partnerships are accelerating development & deepening translational insights for #CER1236 in a recent interview with AlphaStreet Intelligence. Read more: bit.ly/4i0nhys #CERoTherapeutics #CellTherapy

#CERoTherapeutics' CSO, Robert Sikorski, M.D., Ph.D., highlights the dedication of the #CERo team, including CEO, Chris Ehrlich, and Director, Brian Atwood, noting their deep scientific expertise and unwavering focus on patients. Learn more about our team:

$CERo shares a clinical update from its Phase 1 CertainT-1 trial of CER-1236 in #AML. Cell expansion was observed without CRS or ICANS. A patient with #MDS achieved a platelet transfusion-free interval of more than 60 days. An analyst call will be held today at 5 PM ET. PR:

$CERo's CEO, Chris Ehrlich, joins industry leaders in a Pharma's Almanac roundtable exploring how capital constraints are shaping M&A activity and strategic partnerships across pharma and CDMOs. Check out the full roundtable: bit.ly/4aI2spW #Biotech #PharmaTrends #CDMO

Chris Ehrlich, $CERo's CEO, shares his perspective on the advances that have shaped pharma over the past 30 years in a Pharma's Almanac roundtable. He highlights #immunotherapy and engineered T cell approaches as major oncology breakthroughs. Read more: bit.ly/3LnQzen

Progress in engineered T cell therapy at #CERoTherapeutics takes critical thinking and a hands-on approach. #CERo's Director, Brandon Cieniewicz, reflects on the team mindset behind #CER1236. $CERo #CellTherapy #CancerResearch

The latest #CERo newsletter, “A New Year of Advancing Research in Immune Cell Therapy,” dives into the work the $CERo team is doing to advance engineered T cell therapies for patients facing difficult-to-treat #cancers. Read the full edition: bit.ly/49Jliw7

Check out this recent coverage from Discover Pharma highlighting early clinical findings from $CERo's ongoing Phase 1 CertainT-1 trial evaluating CER-1236 in patients with #AML. Full article: bit.ly/49N7Ups #CellTherapy #ClinicalTrials #Biotech

Featuring Michael Byrnes of #CERoTherapeutics' board of directors. Mr. Byrnes brings 20+ years of financial & operational leadership across the #biopharmaceutical industry, supporting $CERo's mission and long-term vision. Learn more about #CERo's team: bit.ly/4lYnZNk

$CERo announces a late-breaking oral poster presentation highlighting interim Phase 1 data from its CERTAIN-T  trial of CER-1236 at #Tandem26 (ASTCT/ CIBMTR). Results showed positive safety and transfusion-independence outcomes in a high-risk #MDS patient. Full PR:

This #WorldCancerDay, we recognize the global effort to advance cancer research and improve patient care. $CERo remains committed to developing innovative cell-based therapies. #CancerResearch #CellTherapy

$CERo announces the appointment of Eric Francois to its Board of Directors. Eric brings 25+ years of life sciences experience across investment banking and public #biotech leadership, with expertise in capital raising, M&A, and business development. Full PR:

This #NationalCancerPreventionMonth, #CERoTherapeutics recognizes the role of prevention, early detection, and innovation in reducing cancer’s impact. Through next-generation cell therapies, $CERo is working to advance new options for patients in need. #CancerPrevention